Press
Pathogenica CSO Speaks at IBC Life Sciences Drug Discovery & Diagnostic Development Week
CAMBRIDGE, MA – August 2, 2011 – Pathogenica, Inc. announced that the Company’s Chief Scientific Officer, Graeme Doran, Ph.D., is speaking today at the IBC Life Sciences Drug Discovery & Diagnostic Development Week, in San Francisco.
During the conference, the only event of its kind focused on the application of next generation sequencing technology for research, diagnostic development, and patient care, Dr. Doran will speak on the theme, "Next Generation Sequencing & Genomic Medicine." In his talk, he will present the development of Pathogenica’s next-generation sequencing assays for clinical diagnostics to deliver greater accuracy at reduced cost. Dr. Doran will also preview forthcoming clinical applications of next generation sequencing for viral genotyping, as well as Pathogenica’s DxSeq technology, and give an evaluation of Pathogenica’s assays in clinical tissue samples.
Dr. Doran received a first class undergraduate degree from the University of Oxford, as well as a Ph.D. in Physiology, studying the genetic epidemiology and molecular biology of human neurological disorders. Since then, he has worked as a postdoctoral scientist at the David H. Koch Center for Integrative Cancer Research at MIT, and at the Department of Pathology, Harvard Medical School, where his projects focused on non-coding RNA biology. He has contributed book chapters and multiple peer reviewed publications in the fields of RNAi and human genetics, and delivered presentations at international conferences. He currently serves as associate editor for the Journal of RNAi and Gene Silencing, and the Journal of Molecular and Genetic Medicine. He joined Pathogenica in 2010.
About Pathogenica
Pathogenica, based in Cambridge, MA, was founded in 2009 to pioneer commercial applications of pathogen sequencing. Pathogenica applies next-generation DNA sequencing technology for rapid multiplex identification of pathogens, drug resistance genes and toxins in patient samples. The founding scientific advisory board (SAB) is comprised of distinguished scientists in the field, including George Church, Harvard Medical School, Ron Davis, Stanford University, W.Ian Lipkin, Columbia University, Andrew Onderdonk, Harvard Medical School and Kun Zhang, University of California.
Pathogenica’s high throughput pathogen detection system is expected to enable rapid and highly sensitive detection of a wide variety of pathogens from patient samples using just a common assay protocol. www.pathogenica.com
CAMBRIDGE, MA – August 2, 2011 – Pathogenica, Inc. announced that the Company’s Chief Scientific Officer, Graeme Doran, Ph.D., is speaking today at the IBC Life Sciences Drug Discovery & Diagnostic Development Week, in San Francisco.
During the conference, the only event of its kind focused on the application of next generation sequencing technology for research, diagnostic development, and patient care, Dr. Doran will speak on the theme, "Next Generation Sequencing & Genomic Medicine." In his talk, he will present the development of Pathogenica’s next-generation sequencing assays for clinical diagnostics to deliver greater accuracy at reduced cost. Dr. Doran will also preview forthcoming clinical applications of next generation sequencing for viral genotyping, as well as Pathogenica’s DxSeq technology, and give an evaluation of Pathogenica’s assays in clinical tissue samples.
Dr. Doran received a first class undergraduate degree from the University of Oxford, as well as a Ph.D. in Physiology, studying the genetic epidemiology and molecular biology of human neurological disorders. Since then, he has worked as a postdoctoral scientist at the David H. Koch Center for Integrative Cancer Research at MIT, and at the Department of Pathology, Harvard Medical School, where his projects focused on non-coding RNA biology. He has contributed book chapters and multiple peer reviewed publications in the fields of RNAi and human genetics, and delivered presentations at international conferences. He currently serves as associate editor for the Journal of RNAi and Gene Silencing, and the Journal of Molecular and Genetic Medicine. He joined Pathogenica in 2010.
About Pathogenica
Pathogenica, based in Cambridge, MA, was founded in 2009 to pioneer commercial applications of pathogen sequencing. Pathogenica applies next-generation DNA sequencing technology for rapid multiplex identification of pathogens, drug resistance genes and toxins in patient samples. The founding scientific advisory board (SAB) is comprised of distinguished scientists in the field, including George Church, Harvard Medical School, Ron Davis, Stanford University, W.Ian Lipkin, Columbia University, Andrew Onderdonk, Harvard Medical School and Kun Zhang, University of California.
Pathogenica’s high throughput pathogen detection system is expected to enable rapid and highly sensitive detection of a wide variety of pathogens from patient samples using just a common assay protocol. www.pathogenica.com